Previous 10 | Next 10 |
Viatris Reports Strong Second Quarter 2022 Results PR Newswire Reports Total Revenues of $4.12 Billion ; U.S. GAAP Net Earnings of $314 Million ; Adjusted EBITDA of $1.48 Billion ; U.S. GAAP Net Cash Provided by Operating Activities of $803 Million ; ...
Viatris ( NASDAQ: VTRS ) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is $0.83 (-15.3% Y/Y) and the consensus Revenue Estimate is $4.18B (-8.7% Y/Y). Over the last 1 year, VTRS has beaten EPS estim...
ANIP , APRN , ASRT , BNTX , CLVS , D , DCTH , DTIL , ELAN , ENR , FREY , GOLD , HE , HEP , ITUB , KNDI , KOS , LINC , OTCPK:LKNCY , OSG , PDSB , PLTR , PRTY , RDWR , RETA , SOHU , TGN...
Viatris is down 40% since the spin-off. Financial metrics are positively increasing as one-time costs of the merger are decreasing. Safe and high dividend yield combined with exceptional free cash flow yield offer a great margin of safety. The restructuring of the company offers a...
Whether you want to collect passive income or record market-beating returns, investing in dividend-paying companies can help you achieve both goals. And with the equities market currently experiencing a downturn, many dividend stocks look reasonably valued. Income-seeking investors have ple...
Teva posted second-quarter results that exceeded market expectations. Teva's outlook looks bright. Opioid settlement another reason the stock added 30% after the earnings report. When Teva Pharmaceutical Industries Limited ( TEVA ) posted second-quarter results, the ...
Using payout ratios to evaluate the health of a dividend stock is a quick way for investors to assess if a payout is too good to be true and due for a cut. Anything over 80% will likely raise some eyebrows, and at more than 100%, investors may skip a stock altogether. However, a payout rati...
Generic drugmaker, Viatris ( NASDAQ: VTRS ) posted three back-to-back sessions of losses to approach a 52-week low on Friday. Over 10.8M of company shares have changed hands so far, compared to the 65-day average volume of ~11.1M. Established in 2020 as a combination of ...
Although the healthcare sector has largely resisted this year's downward pressure, it is likely to succumb as pressure increases. Healthcare stocks have a well-deserved reputation for cyclical defense, but they are more likely to underperform in "secular" bear markets. Healthcare ...
We highlighted three things the bulls needed to be worried about in 2022 the last time we covered Viatris. Our data to date suggests that guidance is likely to suffer, and Q2 should be where it happens. There is some encouraging news for 2023 and that helps the long case. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...